First Patient dosed in Ph 1/1b Clinical Trial of QTX3046
“We are pleased to now have two KRAS inhibitor programs in the clinic focused on treating G12D-mutated cancers,” said Leonardo Faoro, MD, MBA, Chief Medical Officer of Quanta Therapeutics. “The combination treatment with KRAS and EGFR inhibitors has shown promising efficacy in multiple KRASG12C-mutated tumor types. In order to achieve similar breakthroughs against the more prevalent G12D mutation, it will require oral small molecules with direct inhibition of the target and properties enabling use in combination treatments. We believe we are leading the field with the combination of oral, direct inhibition of KRASG12D and EGFR antibody therapy for difficult-to-treat solid tumors.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000